The Place of Angiotensin II Antagonists in Relation to the Canadian Hypertension Society Guidelines
作者： S. George Carruthers
DOI: 10.1007/978-1-4615-5743-2_8
关键词:
摘要: Angiotensin (Ang) II antagonists are a novel class of drugs developed to block Ang receptors. This approach is deemed more direct and likely be effective than the earlier pharmacological inhibiting enzyme (ACE inhibitor) responsible for converting I II. Furthermore, it expected that will avoid problems associated with pathways bypass ACE, e.g., tissue chymase.
springer.com
sci-hub.st 参考文章(19)
R. R. Wexler, A. T. Chiu, D. J. Carini, P. C. Wong, P. B. M. W. M. Timmermans, J. V. Duncia, R. D. Smith, Discovery of losartan, the first angiotensin II receptor antagonist. Journal of Human Hypertension. ,vol. 9, ,(1995)
P. Hamet, J. L. Chiasson, J. K. McKenzie, S. A. Ross, K. G. Dawson, Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. Canadian Medical Association Journal. ,vol. 149, pp. 821- 826 ,(1993)
L. A. Leiter, R. D. Feldman, E. D. Burgess, R. I. Ogilvie, M. G. Myers, J. R. Cusson, Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension Canadian Medical Association Journal. ,vol. 149, pp. 575- 584 ,(1993)
E. L. Schiffrin, P. Larochelle, A. Petrasovits, R. B. Haynes, S. G. Carruthers, Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction Canadian Medical Association Journal. ,vol. 149, pp. 289- 293 ,(1993)
C. I. Gryfe, R. A. Reeves, C. Patterson, J. G. Fodor, J. D. Spence, Report of the Canadian Hypertension Society Consensus Conference: 4. Hypertension in the elderly Canadian Medical Association Journal. ,vol. 149, pp. 815- 820 ,(1993)
Leiter L, de Champlain J, Laidlaw J, Lee Bl, Abbott D, Evans Ce, Battista R, Cameron R, Bass M, Chockalingam A, Recommendations of the Canadian Consensus Conference on Non-Pharmacological Approaches to the Management of High Blood Pressure, Mar. 21-23, 1989, Halifax, Nova Scotia Canadian Medical Association Journal. ,vol. 142, pp. 1397- 1409 ,(1990)
Haralambos P. Gavras, Christina M. Salerno, The Angiotensin II Type 1 Receptor Blocker Losartan in Clinical Practice: A Review Clinical Therapeutics. ,vol. 18, pp. 1058- 1067 ,(1996) , 10.1016/S0149-2918(96)80061-0
Matthew R. Weir, Michelle Elkins, Charles Liss, Arthur J. Vrecenak, Eliav Barr, Jonathan M. Edelman, Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension Clinical Therapeutics. ,vol. 18, pp. 411- 428 ,(1996) , 10.1016/S0149-2918(96)80022-1
Raymond Townsend, Brian Haggert, Charles Liss, Jonathan M Edelman, Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension Clinical Therapeutics. ,vol. 17, pp. 911- 923 ,(1995) , 10.1016/0149-2918(95)80069-7
Yves Lacourci??re, Hans Brunner, Richard Irwin, Bengt E. Karlberg, Lawrence E. Ramsay, Duane B. Snavely, Tom W. Dobbins, Elizabeth P. Faison, Edward B. Nelson, Effects of modulators of the renin—angiotensin—aldosterone system on cough Journal of Hypertension. ,vol. 12, pp. 1387- 1393 ,(1994) , 10.1097/00004872-199412000-00012